VERASTEM INC (VSTM)
Health Care · Oncology / RAS/MAPK pathway-targeted small-molecule therapeutics · NASDAQ
A biopharmaceutical company developing targeted therapies for RAS/MAPK pathway-driven cancers, with a newly FDA-approved combination treatment for KRAS-mutated ovarian cancer and a pipeline focused on direct KRAS G12D inhibition.
What VERASTEM INC does
Verastem Inc. is a biopharmaceutical company developing and commercializing therapies that target RAS/MAPK pathway-driven cancers. The company markets AVMAPKI FAKZYNJA CO-PACK (avutometinib plus defactinib), approved by the FDA in May 2025 for adults with KRAS-mutated recurrent low-grade serous ovarian cancer. The pipeline includes VS-7375, a selective oral KRAS G12D dual ON/OFF inhibitor in Phase 1/2 development for pancreatic, lung, and colorectal cancers, along with additional programs targeting FAK inhibition and partnered early-stage assets through GenFleet Therapeutics.
Themes: oncology, KRAS-mutated cancer therapeutics, RAF/MEK pathway inhibition, FAK pathway inhibition, targeted cancer therapy
Fundamentals
- Price$6.89 as of 2026-08-21 close
- Market cap$624M as of 2026-08-21
- 1-year return-20.2% 2025-08-21 close $8.63 → 2026-08-21 close $6.89
- P/En/a negative earnings
- Net margin-391.2% as of 2026-08-24
- Gross margin+85.1% as of 2026-08-24
- ROE-163.6% as of 2026-08-24
- Debt / equity1.01 as of 2026-08-24
- Revenue growth (YoY)+209.1% as of 2026-08-24
- Revenue CAGR (3y)+97.0% SEC XBRL
- Beta0.48 as of 2026-08-24
- Last reported earnings2026-08-06 SEC EDGAR Form 8-K (Item 2.02)
How VSTM compares in its sector
- net profit marginbottom 25% 504 covered Health Care peers, as of 2026-08-24
- operating marginbottom 25% 504 covered Health Care peers, as of 2026-08-24
- gross margintop 25% 384 covered Health Care peers, as of 2026-08-24
- return on equitybottom 25% 576 covered Health Care peers, as of 2026-08-24
- 3-year revenue CAGRtop 10% 402 covered Health Care peers
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
How VERASTEM INC looks technically
VERASTEM INC (VSTM) is trading 8.6% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed below its 200-day average about 129 trading days ago — a "death cross", a bearish long-term signal. A strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 45, with buyers in control. Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 60, neither overbought (above 70) nor oversold (below 30). MACD, a trend-momentum gauge, turned bearish about 1 trading day ago (its momentum flipped negative). It made a new 20-day high about 4 trading days ago. It is 38.8% below its highest point of the past year. Trading volume is unusually light — only about 45% of its 30-day average.
Trend
9
| Distance from the 200-day | it is trading 8.6% above its 200-day average, the long-term trend line — a longer-term uptrend | +8.6% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $5.47 | $5.47 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $6.34 | $6.34 |
| Swing structure | each recent peak has been higher than the one before it and each dip has been shallower — the pattern chart-watchers call an uptrend, which describes where price has already been and not where it goes next | higher highs and higher lows |
| Last swing turn | its last significant turn was a swing low 21 calendar days ago — the swings before that are what the structure reading is measured on | 21 sessions |
| Wave structure | its recent swings can be read as a five-part upward sequence — what Elliott-wave chartists call an impulse — now in leg 3 of five; the labelling fails if price closes below 5.545. It is one of several labellings that fit, and it describes the swings already printed, not what comes next. The same swings also read as a three-part correction in leg C. | possible upward five-wave sequence, in wave 3 (one of several readings) |
| Since the 50/200 cross | its 50-day average crossed below its 200-day average about 129 trading days ago — a "death cross", a bearish long-term signal | 129 sessions |
| Above the 200-day after a dip | it recently dipped to its 200-day average (the long-term trend line) and has since climbed back above it — now about 8.6% above | +8.6% |
| Trend strength (14-day ADX) | a strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 45, with buyers in control | 45.1 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 60, neither overbought (above 70) nor oversold (below 30) | 59.5 |
|---|---|---|
| Position in its 14-day range | it is trading in the upper half of its 14-day range ($5.64 to $7.85) — its "stochastic" reading is 57 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been slipping within that range over the last few sessions. | 56.6 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, turned bearish about 1 trading day ago (its momentum flipped negative) | 1 session |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $11.25 | $11.25 |
|---|---|---|
| From the 52-week high | it is 38.8% below its 52-week high (its highest price of the past year) | -38.8% |
| Above the 52-week low | it is 100.9% above its 52-week low (its lowest price of the past year) | +100.9% |
| Below the 52-week high | it is 38.8% below its highest point of the past year | 38.8% |
| Since a 20-day breakout | it made a new 20-day high about 4 trading days ago | 4 sessions |
| Since a 55-day breakout | it made a new 55-day high about 4 trading days ago | 4 sessions |
| All-time high | its highest closing price on record is $226.75 (set on 2013-07-11) | $226.75 |
| Given back of the 52-week move | over the past year its closes ranged ($3.45 to $10.77), and it has recovered around half of its fall from last year’s high — 47% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $7.97 to $8.21. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 47.0% |
| From the all-time high | it is 97.0% below its all-time high | -97.0% |
| Nearest price level | it is trading 1.8% below a resistance level at $7.01 — a price it turned at twice since 2025-10-20, most recently on 2026-02-05. Since 2024-08-21 it has 12 such levels below the current price and 5 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | +1.8% |
| All-time low | its lowest closing price on record is $2.10 (set on 2024-08-05) | $2.10 |
| Above the all-time low | it is 228.1% above its all-time low | +228.1% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are about average versus its own recent 6-month history | 68th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $0.4666 between its high and its low — about 6.8% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $0.4666 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $5.41 and $7.58 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $5.41 – $6.49 – $7.58 |
| Typical daily range (% of price) | its price moves about 6.8% in a typical session — more volatile than most companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 6.8% |
| Stretch from the 200-day average | it is trading 1.2 daily ranges above its 200-day average price (8.6% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 1.2 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is unusually light — only about 45% of its 30-day average | 0.45× |
|---|
Analyst
2
| Change in the average price target | analysts have cut their average price target by 0.8% since the prior reading | -0.8% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Candlestick patterns
2
| Since a doji | today it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | today |
|---|---|---|
| Since a bullish engulfing | 4 sessions ago it opened below the previous session's close and finished above that session's open — a "bullish engulfing" pair, where one up day more than undid the down day before it | 4 sessions ago |
Price gaps
3
| Gap at the open | it opened on 2026-08-21 0.9% above the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | +0.9% |
|---|---|---|
| Open gap | it gapped 12.5% above the previous close 10 sessions ago and has not traded back through the level it left behind at 5.91 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | +12.5% |
| Gap filled | a 3.0% gap up opened on 2026-08-19 has been "filled" 2 sessions ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 2 sessions ago |
Price streaks
1
| Closing streak | it closed higher in its latest session, after a session that did not close higher — a single up day rather than a run | 1 session up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock beat the market by 12.5 percentage points (the stock gained 14.8% while the market gained 2.3%) | +12.5% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock beat the market by 58.3 percentage points (the stock gained 61.4% while the market gained 3.1%) | +58.3% |
| vs market, 6 months | over the past 6 months this stock beat the market by 5.1 percentage points (the stock gained 16.2% while the market gained 11.1%) | +5.1% |
| vs market, 12 months | over the past 12 months this stock lagged the market by 40.6 percentage points (the stock lost 20.2% while the market gained 20.5%) | -40.6% |
Signal agreement
2
| Bullish technical signals | 4 of the 9 technical signals we can compute for it are currently in a bullish state: a strong uptrend, with buyers in control, trading above its 200-day average, outperforming the market over 6 months, trading above the Ichimoku cloud — these describe past price behaviour, not a forecast | 4 of 9 |
|---|---|---|
| Bearish technical signals | 2 of the 9 technical signals we can compute for it are currently in a bearish state: a "death cross" — its 50-day average is below its 200-day, MACD momentum is negative — these describe past price behaviour, not a forecast | 2 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 41% above the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-16 and projected forward over today's price, the side traders read as an established uptrend, with the band below acting as the level that would have to give way. The band itself is thin, spanning 1.9% of the share price, which is taken to mean a barrier that gives way easily. | +41.1% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 24% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $5.54 — a volume-weighted average of daily closes over 158 sessions, not a true tick-by-tick VWAP. | +24.4% |
|---|---|---|
| Vs the average paid since it last reported | the price is sitting right on the average price paid since it last reported on 2026-08-06 (its 10-Q), so the typical buyer over that stretch is roughly break-even. That average is $6.88 — a volume-weighted average of daily closes over 12 sessions, not a true tick-by-tick VWAP. | +0.2% |
Price levels it has turned at before
VSTM last closed at $6.89 on 2026-08-21. Since 2024-08-21 it has turned at 12 prices below its last close and 5 above; the 3 nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $7.01 | Resistance | 1.8% above the last close | turned there twice · 2025-10-20 to 2026-02-05 |
| $6.76 | Support | 1.9% below the last close | turned there four times · 2025-07-30 to 2026-04-17 |
| $7.28 | Resistance | 5.6% above the last close | turned there twice · 2025-01-03 to 2025-11-14 |
| $6.48 | Support | 6.0% below the last close | turned there twice · 2025-01-31 to 2026-07-27 |
| $7.59 | Resistance | 10.2% above the last close | turned there twice · 2025-03-12 to 2025-12-19 |
| $6.03 | Support | 12.5% below the last close | turned there twice · 2024-12-06 to 2026-02-02 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a five-part upward sequence — what Elliott-wave chartists call an impulse — now in leg 3 of five.
This labelling fails — stops being a possible reading at all — if it closes below $5.54.
This is one of several labellings that fit the same swings, so treat it as a reading rather than the reading. It was chosen from 2 labellings that survived the rules, counting shorter readings of the same bars.
On past moves of this shape the leg has usually ended somewhere between $8.58 and $10.45 — that is where it has tended to end if the count holds, not a forecast of where the price goes.
Alternate reading: The same swings also read as a three-part correction in leg C, which fails on a close below $5.54.
This labelling was already in place when we began recording count changes on 2026-08-13, so how long it has stood is not something we can say yet.
Read from daily closes as of 2026-08-21.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · Tested and reclaimed 200-day support · Pulled back from the 12-month high · MACD just crossed bearish (12/26/9) · in a strong, established uptrend (ADX) · beating the market | Learn: moving average · golden cross · adx · rsi · macd · breakout · fifty two week high low · volume and relative volume
Based on daily closing prices as of 2026-08-21. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingStrong Buy (1.11 mean, 1=Strong Buy…5=Strong Sell) — 8 analysts
- Mean price target$14.75 range $9.00 – $18.00; median $15.00
Analyst estimates, as of 2026-08-18. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for VSTM
- Consensus EPS estimate-$0.43 next reporting period, as of 2026-08-18
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Regulatory and reimbursement uncertainty: While AVMAPKI FAKZYNJA CO-PACK received accelerated approval, commercial success depends on label expansion through RAMP 301, favorable reimbursement decisions by third-party payors including government agencies, and potential policy actions that may adversely affect the business.","Clinical trial and commercialization execution: Success relies on timely enrollment and positive results from ongoing trials (RAMP 301, RAMP 205, VS-7375-101), manufacturing/supply chain continuity, and competitive pressure from other companies developing KRAS and RAF/MEK inhibitors.","Early-stage pipeline and financial sustainability: The company is unprofitable with significant operating losses (net margin -391.16%), and most pipeline programs are in early clinical or preclinical stages; long development timelines and clinical trial uncertainties pose risks to future revenue generation and going concern."]
What changed in the latest 10-Q
AI-assisted comparison of VSTM's 10-Q filed 2026-05-07 against the prior one filed 2025-11-04.
Management's Discussion & Analysis (MD&A)
- Added:
- Newer filing references 'challenging RAS/MAPK pathway-driven cancers' vs older 'RAS MAPK pathway-driven cancers'
- Newer filing specifies AVMAPKI FAKZYNJA CO-PACK as 'the first treatment specifically FDA-approved' with explicit KRAS-mutated LGSOC indication in overview
- Newer filing added statement 'In April 2026, we announced new two-year median follow up data from the Phase 2 RAMP 201 trial' with SGO 2026 meeting presentation details
- Newer filing added extensive VS-7375 clinical trial updates including: April 2026 TARGET-D branding announcement, dose evaluation at 1200 mg QD and 900 mg QD with cetuximab, initiation of three Phase 2 registration-directed trials (TARGET-D 201, 202, 203)
- Newer filing added March 2026 AACR meeting abstract selection details regarding VS-7375 combination with PRMT5 inhibition in MTAP-deleted KRAS G12D pancreatic cancer
- Newer filing states RAMP 301 'was fully enrolled, as of December 2025' vs older filing stating enrollment 'completed a full quarter early in September of 2025' with IDMC recommendation for additional 29 patients
- Newer filing references exposure-response analysis demonstrating 'the approved dose and schedule of avutometinib plus defactinib achieve the optimal therapeutic effect'
- Removed:
- Older filing's detailed description of RAMP 201 study initiation ('In the fourth quarter of 2020') and its adaptive two-part design details removed from newer filing
- Older filing's explanation of 'RAMP' acronym meaning 'RAF and MEK Program' not present in newer filing
- Older filing's detail about May 8, 2025 FDA approval timing and accelerated approval pathway language removed from newer filing
- Older filing's detail about NCCN guideline submission process and October 2025 NCCN Committee meeting removed from newer filing
- Older filing's RAMP 201J Japan Phase 2 trial details (October 2024 start, IGCS 2025 meeting, April 11, 2025 data extract date, November 5, 2025 embargo lift) removed from newer filing
- Older filing's RAMP 203 study details regarding Amgen collaboration and LUMAKRAS combination therapy removed from newer filing
- Reworded:
- Older 'development and commercialization' changed to newer 'developing and commercializing' in opening description
- Older 'committed to the development and commercialization of new medicines' changed to newer 'committed to developing and commercializing new medicines'
- Older reference to Form 10-K 'for our fiscal year ended December 31, 2024' changed to newer 'for our fiscal year ended December 31, 2025'
- Older 'KRAS mt' changed to newer 'KRAS-mutated' in product description
- Older 'received' changed to newer 'have received' in indication description
- Older 'is designed to provide' changed to newer 'was designed to provide' for defactinib/avutometinib combination description
- Newer filing uses 'COMMERCIAL PRODUCTS' and 'CLINICAL PIPELINE' as section headers; older filing integrates product information differently
- Notes:
- The newer filing text appears truncated at the end ('In March 2026, we reported an update on'), preventing full comparison of concluding sections
- Older filing section on RAMP 203 Amgen collaboration also truncated ('recommended Phase 2 dose of 4 mg avutometinib in combination wi'), limiting full comparison
- Document quality and formatting inconsistencies present in both filings make some textual comparisons approximate
Risk Factors
- Added:
- Newer filing (2026-05-07) adds reference to 'VS-7375, and others' in the list of compounds for combination development with avutometinib
- Newer filing (2026-05-07) adds 'uncertainties related to the regulatory and policy actions proposed and enacted by the current U.S. presidential administration that may adversely affect our business'
- Newer filing (2026-05-07) adds 'whether preclinical testing of our product candidates and preliminary or interim data from clinical trials will be representative of more mature data or predictive of the results' language
- Removed:
- Older filing (2025-11-04) includes 'the potential for additional development programs involving the Company's lead compound' - newer filing (2026-05-07) changes 'the Company's' to 'our'
- Older filing (2025-11-04) lists 'avutometinib in combination with other compounds, including defactinib, LUMAKRAS® and others; and VS-7375' - newer filing (2026-05-07) reorganizes to 'avutometinib in combination with other compounds, including defactinib, LUMAKRAS®, VS-7375, and others'
- Older filing (2025-11-04) states 'uncertainties related to the recent change in the U.S. presidential administration, including regulatory and policy changes' - newer filing (2026-05-07) removes reference to 'recent change' and 'recent'
- Older filing (2025-11-04) includes 'risks associated with preliminary and interim data, which may not be representative of more mature data, including with respect to interim duration of therapy data' - language not present in newer filing (2026-05-07)
- Older filing (2025-11-04) includes 'that we may be unable to successfully initiate or complete the clinical development and eventual commercialization of our product candidates' - not present in newer filing (2026-05-07)
- Reworded:
- Quarter end date changed from 'September 30, 2025' (older filing 2025-11-04) to 'March 31, 2026' (newer filing 2026-05-07)
- Form 10-K filing date reference changed from 'filed with the Securities and Exchange Commission ("SEC") on March 4, 20' incomplete in older to similar incomplete reference in newer
- Trademark symbols: AVMAPKI™ FAKZYNJA™ in older filing (2025-11-04) changed to AVMAPKI® FAKZYNJA® in newer filing (2026-05-07)
- Notes:
- The newer filing text provided is truncated at the end ('March 4, 20'), limiting full comparison of final forward-looking statement language
- Older filing text is also truncated at the end, preventing complete comparison of full risk factors section
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
0 open-market purchases and 4 open-market sales by insiders in the last 90 days.
- Last 30 days0 buys · 1 sell ($7565) — 1 selling insider
- Last 90 days0 buys · 4 sells ($111895) — 2 selling insiders
- Last 180 days0 buys · 5 sells ($116585) — 2 selling insiders
Activity heuristic: net selling (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-08-03. As of 2026-08-24.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about VSTM's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
4 institutional 13F filers reported holding VSTM as of 2026-03-31 (quarter-end position, filed within 45 days).
- Distinct 13F filers 4
- Reported shares held 12,561,502
- Reported value $66,575,961
reported quarterly holdings change (2025-12-31 → 2026-03-31): 0 new, 3 increased, 1 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Short interest (FINRA)
VSTM had 19,825,791 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
VSTM had 21.9% of its shares outstanding sold short as of the 2026-07-31 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 9.35 days to cover at the same settlement.
- Reported short interest (shares) 19,825,791
- Short interest (% of shares outstanding) 21.9%
- Prior settlement (shares) 20,103,345
- Reported change -1.38%
- Days to cover (reported) 9.35
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Amgen (AMGN)
- Mirati Therapeutics (acquired by Bristol Myers Squibb)
- Revolution Medicines (RVMD)
- BridgeBio Pharma (BBIO)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare VSTM vs…
VERASTEM INC is found in…
VSTM ranks in…
Frequently asked questions
What does VERASTEM INC (VSTM) do?
Verastem Inc. is a biopharmaceutical company developing and commercializing therapies that target RAS/MAPK pathway-driven cancers. The company markets AVMAPKI FAKZYNJA CO-PACK (avutometinib plus defactinib), approved by the FDA in May 2025 for adults with KRAS-mutated recurrent low-grade serous ovarian cancer.
What sector is VERASTEM INC (VSTM) in?
VERASTEM INC (VSTM) is classified in the Health Care sector. Its industry is Oncology / RAS/MAPK pathway-targeted small-molecule therapeutics. It trades on NASDAQ.
Who are VERASTEM INC's (VSTM) competitors?
Notable peers of VERASTEM INC (VSTM) include Amgen, Mirati Therapeutics (acquired by Bristol Myers Squibb), Revolution Medicines and BridgeBio Pharma. This peer set is informational only — not financial advice.
Is VERASTEM INC (VSTM) overbought or oversold right now?
VERASTEM INC (VSTM) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 60, in the neutral middle (as of 2026-08-21). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on VSTM come from?
Fundamentals and prices come from market data, as of 2026-08-24; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.